Post on 18-Nov-2014
transcript
Ranbaxy
By: Punit Sahu
Content’s Introduction History Mission and Vision Values Life @ Ranbaxy Ranbaxy –Daiichi Sankyo Partnership Corporate Social Responsibility R & D Board of Director’s Ranbaxy's Top Products Global manufacturing strength Global sales Market shares & market review Contact us!!!!!
Introduction
Ranbaxy is the India's largest pharmaceutical company,
Incorporated in1961. Headquarters Located in Gurgaon,
Haryana,india.
The company went public in 1973, and Japanese company Daiichi Sankyo gained majority control in 2008. . Worldwide Presence
Ground presence in 46 countries, products sold in over 125 countries. Manufacturing locations in 7 countries.
Atul Sobti is currently Ranbaxy CEO and M.D., having taken over from Malvinder Singh in May 2009.
Cont… History of Ranbaxy
Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi.
The name Ranbaxy is a portmanteau word from the names of its first owners Ranbir and Gurbax.
Bhai Mohan Singh bought the company in 1952 and after that Mohan Singh and Shivinder Mohan Singh sold the company to the Japanese company
Daiichi Sankyo in June 2008.
CORPORATE OFFICECORPORATE OFFICE
Mission
To become a Research-based International Pharmaceutical Company
Vision –2012
Achieve significant businessin proprietary prescription products by 2012with a strong presence in developed markets
Aspirations –2012
•Aspire to be a $5 Billion Company•Become a Top 5 Global Generics Player
•Significant Income from Proprietary Products
•Achieving customer satisfaction is fundamental of business
•Provide products and services of the highest quality
•Practice dignity and equity in relationship and provide opportunities for our people to realise their full potential
•Ensure profitable growth and enhance wealth of the shareholders
•Foster mutually beneficial relations with all our business partners
•Manage our operations with high concern for safety and environment
•Be a responsible corporate citizen
value
Life @RanbaxyA career at Ranbaxy means an opportunity for ample learning & growth. A career at Ranbaxy means an opportunity for ample learning & growth. It offers avenues to work across the globe along side the finest minds. The It offers avenues to work across the globe along side the finest minds. The Company offers a challenging assignment, a world class working Company offers a challenging assignment, a world class working environment, professional management, competitive salaries, stock options environment, professional management, competitive salaries, stock options along with exceptional rewards.along with exceptional rewards.If you have an appetite for challenges, we have an exciting career for youIf you have an appetite for challenges, we have an exciting career for you
OpportunitiesOpportunities
The global spread of Ranbaxy and the blazing growth in business The global spread of Ranbaxy and the blazing growth in business provides ample opportunities for our employees to build careers in provides ample opportunities for our employees to build careers in various fields.various fields.Our managers will generally have the opportunity to live and Our managers will generally have the opportunity to live and work in different countries; such international experience will work in different countries; such international experience will help them better understand our complex business and grow help them better understand our complex business and grow both personally and professionally.both personally and professionally.
•A path breaking confluence that redefines the global pharma paradigm..
•Provides solutions to key need-gaps for each organization.
•Strategic combination creates an Innovator and Generic Pharmaceutical Powerhouse.
•Combined entity is ranked among the Top 20 global pharmaceutical companies
•Ranbaxy enters into a new orbit to chart a higher trajectory.
•Complementary strengths ranging from excellence in NDDR to extensive reach across globalmarkets.
•Financially & strategically beneficial for all stakeholders.
Ranbaxy –Daiichi Sankyo Partnership
Corporate Social ResponsibilityCREATING VALUE…VALUING LIFE…
• An essential component of Ranbaxy's CSR is
to care for the community.
• Based on the theme „Health For All‟ setupRanbaxy Rural Development Trust‟ in 1978; later re-christened as „Ranbaxy Community Health Care Society‟ in 1994.
• Operates in the states of Punjab, Haryana,
H.P.,MP.and Delhi /Gurgaon to provide
integrated health care to about 2 lakh peoplestaying in 100 villages and urban slum areas…..
Research & Development
Dr. Sudershan K. Arora (L)President - R&D (Generics, NDDS & Drug Development)Dr. Pradip Kumar Bhatnagar (R)Sr. Vice President, New Drug Discovery Research
State-of-the-art R&D facilitiesbased in India
R&D I R&D IIR&D III
R&D IV
Research & Development•Dedicated Facilities for Innovative & Generics Research
•1400 R&D Personnel ( ~ 300 Doctorates)
•Highest R&D spender across industry
•8 -10 NCE molecules in pipeline
•NDDS based products (4 platform technologies) •R&D collaborations
Alliance / Collaboration in NDDR
Out-licensingIn NDDS
Out-licensingIn NDDS
Alliance / Collaboration in NDDR
Chairman, CEO & M.D.Chairman, CEO & M.D.
Dr. Tsutomu Une Chairman
Malvinder Mohan SinghChairman, CEO & M. D.
Board of Directors
Dr. Tsutomu UneChairman Non Executive & Non Independent Director
Mr. Atul SobtiC E O & M D
Mr. Takashi ShodaNon Executive &Non Independent Director
Dr. Anthony H. WildIndependent Director
Mr. Rajesh V. ShahIndependent Director
Mr. Rajesh V. ShahIndependent Director
Mr. Percy ShroffIndependent Director
Ranbaxy’s Top Products
for the treatment of brain cancer, for the treatment of brain cancer, pancreatic cancerpancreatic cancer
SimvastatinSimvastatin
control control hypercholesterolemia & to prevent cardiovascular disease
AmoxiClav PotassiumAmoxiClav PotassiumUsed to treat a broad-spectrum of bacterialUsed to treat a broad-spectrum of bacterial infections,infections,
IsotretinoinIsotretinoin
CiprofloxacinCiprofloxacin
It kills bacteria by interferingIt kills bacteria by interfering
OmeprazoleOmeprazole
used in the treatment of used in the treatment of dyspepsia
Developed Markets Presence
•Largest generic market worldwide•Significant patent expiries through 2011
•Germany, UK -mature markets •France, Spain, Italy, Romania -emerging markets•Ranbaxy has presence in 23 of the 27 EU countries
•Mature generic market•Ranbaxy is the fastest growing generics company in Canada
•Emerging generic market, < 5% generic penetration•1stIndian pharma company
USA
EU
CANADA
JAPAN
Global Manufacturing Strengths• cGMP compliant world-class API & Dosage Forms
manufacturing facilities across the globe• 7 manufacturing locations worldwide• API facilities -increasing vertical integration• Creating capacities for specialty products• New facilities added in cost advantageous geographies
USA Ireland Romani
a
Malaysia South Africa India
Nigeria
CIS
North America
Europe API
RoW
Asia
Global Sales (2009): US $ 1519Mn
Global Sales Split
Emerging54%
Others7%
Developed39%
FY 2005 FY 2009•Improving balance in market mix•Growth well spread across geographies•Positioned to leverage various market opportunities.
Evolution of Market Mix
Market Share of RanbaxyMarket Share of Ranbaxy
Global Markets Mix 2008Global Markets Mix 2008
54% & Emerging
The Company is currently ranked 2nd in the Indian pharmaceutical market with 4.98% market share (IMS, Oct-Dec’09).
Global sales in 2009 were USD 1,519 Mn (Rs. 73,441 Mn), De-growth of 9% over previous year. In Rupee terms, sales grew moderately by 1%. Sales during the Quarter recorded growth of 25% at USD 482 Mn (Rs. 22,699 Mn). Emerging markets accounted for 54% of sales during the year, while developed markets contributed 39%.
REVENUE AND PROFIT AFTER TAX
Key competitorsKey competitors
GlaxoSmithKline
RPG Enterprises
East India Pharmaceutical
Dr. Reddy's Laboratories
Cipla Ltd
Dabur India Ltd
Forecasts For 2010, the company forecast a 48% growth in net profit to
Rs460 crore from Rs311 crore in 2009, and a 6% rise in sales to around Rs7,800 crore.
“Ranbaxy’s overall numbers appear fine but their guidance for 2010 is disappointing,” said a Mumbai-based analyst with a foreign brokerage, asking not to be named as he’s not authorized to speak to the media.
“If they will have sales revenue from exclusive launches of generic versions of Valtrex and Flomax as well as Nexium supplies to AstraZeneca Plc in 2010, then why will growth in the year be only 6% on sales?”
The December quarter’s profit was backed by revenue from the exclusive launch of two major drugs in the US—generic versions of anti-herpes drug Valtrex and epilepsy medicine Trileptal—and a hold on costs in various markets, including in Europe
Ranbaxy Laboratories LimitedCorporate Office
Plot 90, Sector 32, Gurgaon -122001 (Haryana), INDIA
Ph: 91- 124- 4135000Fax: 91-124-4135001
Web site:- www.ranbaxy.com